Cargando…

Editorial: Novel targeted drugs for indolent lymphoid malignancies

Detalles Bibliográficos
Autores principales:	Robak, Tadeusz, Puła, Bartosz, Hus, Iwona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332945/ https://www.ncbi.nlm.nih.gov/pubmed/37434970 http://dx.doi.org/10.3389/fonc.2023.1224528

Ejemplares similares

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
por: Hus, Iwona, et al.
Publicado: (2022)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Editorial: The notch signaling pathway in lymphoid malignancies
por: Fais, Franco, et al.
Publicado: (2023)

Editorial: Role of the antigen receptor in the pathogenesis of B-cell lymphoid malignancies
por: Agathangelidis, Andreas, et al.
Publicado: (2023)

Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets
por: Cavallari, Ilaria, et al.
Publicado: (2023)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

Editorial: Biological aspects of targeted drug discovery: Development of novel targets and/or chemotherapies, and drug repurposing
por: Kalra, Rajkumar Singh, et al.
Publicado: (2022)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021)

Liquid biopsies and minimal residual disease in lymphoid malignancies
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Editorial: Advances of Targeted Therapy in Gynecologic Malignancies
por: Qiu, Haifeng, et al.
Publicado: (2022)

Editorial: The advances in proteomics and targeted therapy of malignant brain tumours
por: Chen, Anjing, et al.
Publicado: (2023)

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies
por: Mędra, Aleksandra, et al.
Publicado: (2016)

Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells
por: Vetro, Calogero, et al.
Publicado: (2015)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

Editorial: RNA recognition landscapes and anticancer drug targeting
por: Salvati, Erica, et al.
Publicado: (2023)

Editorial: Novel Targets and Targeting Technologies to Modulate Tumor Microenvironment
por: Prakash, Jai, et al.
Publicado: (2016)

Editorial: Ubiquitin-Modifying Enzymes as Drug Targets and Biomarkers in Cancer
por: Bell, Jessica L., et al.
Publicado: (2021)

Editorial: Epidemiological trends in hematological malignancies
por: de Lima, Marcos, et al.
Publicado: (2023)

Editorial: The role of imaging in gynecological malignancies
por: Han, Kathy, et al.
Publicado: (2023)

Editorial: Ferroptosis in malignant brain tumors
por: Yakubov, Eduard, et al.
Publicado: (2023)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

Editorial: Novel targets for ovarian cancer stem cells
por: Wang, Yinu, et al.
Publicado: (2023)

Editorial: Novel Molecular Targets and Treatments for Gastroesophageal Cancer
por: Lam, Alfred King-yin, et al.
Publicado: (2022)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

Editorial: Molecular predictive pathology in gynecologic malignancies
por: Malapelle, Umberto, et al.
Publicado: (2023)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Editorial: Case reports in hematological malignancies: 2022
por: Antar, Ahmad, et al.
Publicado: (2023)

Editorial: The Role of Platelets in Cancer Progression and Malignancy
por: Schlesinger, Martin, et al.
Publicado: (2021)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

Editorial: Linking cellular metabolism to hematological malignancies
por: He, Xiujing, et al.
Publicado: (2022)

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

Editorial: Implementation of novel drugs and modern radiotherapy in the treatment of lymphoma patients
por: Levis, Mario, et al.
Publicado: (2023)

Editorial: Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets
por: van Vugt, Marcel A. T. M., et al.
Publicado: (2015)

Histone Modifications and Their Targeting in Lymphoid Malignancies
por: Fernández-Serrano, Miranda, et al.
Publicado: (2021)

Editorial: Diagnosis and treatment of gynecologic malignancies during pregnancy
por: Wang, Yudong, et al.
Publicado: (2023)

Editorial: Intraoperative radiotherapy for gastrointestinal malignancy: updated evidence
por: Masaki, Tadahiko, et al.
Publicado: (2023)

Editorial: The management of hematologic malignancies in lower-income countries
por: Ganesan, Prasanth, et al.
Publicado: (2023)

Editorial: Deciphering the bone marrow microenvironment in hematologic malignancies
por: Wobus, Manja, et al.
Publicado: (2023)

Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies
por: Tse, Ka Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h0vkm5ujkghch798dpbpro0pop